Atea Pharmaceuticals

Atea Pharmaceuticals(AVIR)

BOSTON, MA
Pharmaceutical

Focus: Nucleoside and nucleotide analogs to inhibit the viral RNA polymerase

Atea Pharmaceuticals is a life sciences company focused on Nucleoside and nucleotide analogs to inhibit the viral RNA polymerase.

NeurologyGene Therapy
Funding Stage
PUBLIC
Open Jobs
0

Pipeline & Clinical Trials

A Six-Month Follow-Up Study of Participants With Coronavirus Disease 2019 (COVID-19) Previously Enro
COVID-19
N/A
Buprenorphine/Naloxone + BEM/RZR
Healthy Volunteer Study
Phase 1
Clinical Trials (1)
NCT07314346Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone
Phase 1
Drug: AT-527 + rosuvastatin
Healthy Volunteer Study
Phase 1
AT-527 + digoxin
Healthy Volunteers Study
Phase 1
AT-527 Formulation 1
Healthy Volunteer Study
Phase 1
Clinical Trials (1)
NCT04711187Study of AT-527 in Healthy Subjects (R07496998)
Phase 1
AT-752
Dengue
Phase 1
Clinical Trials (1)
NCT05366439Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model
Phase 1
Cohort 1 BEM + Ruzasvir
Healthy Volunteer Study
Phase 1
Clinical Trials (1)
NCT05731843Drug-drug Interaction Study of Ruzasvir and Bemnifosbuvir
Phase 1
AT-527 550 mg + midazolam
Healthy Volunteer Study
Phase 1
AT-527 550 mg + cyclosporine
Healthy Volunteer Study
Phase 1
Clinical Trials (1)
NCT04849299Effect of Cyclosporine on the Pharmacokinetics (PK) of AT-527 (R07496998)
Phase 1
Phase 1
Clinical Trials (1)
NCT06204679Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir
Phase 1
Clinical Trials (1)
NCT04877769Bronchopulmonary PK of AT-527 (R07496998)
Phase 1
Phase 1
Clinical Trials (1)
NCT05618314Study of AT-527 in Subjects With Normal and Impaired Renal Function
Phase 1
Digoxin vs Digoxin + BEM/RZR vs Digoxin + 2h BEM/RZR
Healthy Volunteer Study
Phase 1
Clinical Trials (1)
NCT06921941Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and Rosuvastatin
Phase 1
Period 1: AT-527 550 mg
Healthy Volunteer Study
Phase 1
Clinical Trials (1)
NCT05004415Mass Balance Study of AT-527 in Healthy Adult Male Subjects (R07496998)
Phase 1
Phase 1
Clinical Trials (1)
NCT05905497The Study of Bemnifosbuvir in Healthy Japanese Subjects
Phase 1
Bemnifosbuvir
Healthy Volunteer
Phase 1
Clinical Trials (1)
NCT05724693Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function
Phase 1
Phase 1
Clinical Trials (1)
NCT05256732Study of AT-527 in Healthy Subjects Under Fasting Conditions or With a Meal
Phase 1
Ethinyl Estradioll/Levonorgestrel
Healthy Volunteer Study
Phase 1
Clinical Trials (1)
NCT07272889Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)
Phase 1
Treatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting
Healthy Volunteer Study
Phase 1
Clinical Trials (1)
NCT07007806Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir
Phase 1
Cohort 1: Days 1-7 Bemnifosbuvir
Healthy Volunteer Study
Phase 1
Clinical Trials (1)
NCT06356194Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/Ruzasvir
Phase 1
AT-752
Dengue
Phase 1
Clinical Trials (1)
NCT04722627Study of AT-752 in Healthy Subjects
Phase 1
Phase 1
Clinical Trials (1)
NCT05905484Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects
Phase 1
Phase 1
Clinical Trials (1)
NCT06911320Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
Phase 1
Phase 1
Clinical Trials (1)
NCT03219957Study of AT-527 in Healthy and HCV-Infected Subjects
Phase 1
Phase 1/2
Clinical Trials (1)
NCT04309734Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects
Phase 1/2
AT-527
COVID-19
Phase 2
Phase 2
Clinical Trials (1)
NCT04019717Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection
Phase 2
Phase 2
Clinical Trials (1)
NCT05904470A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
Phase 2
AT-527
COVID-19
Phase 2
Clinical Trials (1)
NCT04396106Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) in a Hospital Setting
Phase 2
Phase 2
Clinical Trials (1)
NCT05466240Study of AT-752 in Patients With Dengue Infection
Phase 2
Phase 3
Clinical Trials (1)
NCT06868264C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV
Phase 3
RO7496998
COVID-19
Phase 3
Phase 3
Clinical Trials (1)
NCT07037277C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV
Phase 3
Clinical Trials (1)
NCT05629962SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19
Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 28 clinical trials
SEC Filings: 2 available

Financials (FY2025)

R&D Spend
$144M26%
Net Income
-$168M
Cash
$65M